HRMY
Harmony Biosciences Holdings, Inc.$30.20-0.56 (-1.82%)Prev Close$30.76·MCap$1.79B·P/E12.18·Vol262.8K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
13
$5.92M
◆
Net Activity
Net Seller
$5.92M
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Harmony Biosciences Holdings, Inc. (HRMY) has been exclusively selling, with 0 insider purchases totaling $0.00 and 13 insider sales totaling $5.92M. The most recent insider transaction was by Kapadia Sandip (officer: CHIEF FINANCIAL OFFICER), who sold $139.2K worth of shares on Jan 28, 2026. Harmony Biosciences Holdings, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.79B.
HRMY Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 28, 2026 | Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | Sell | 3,746 | $37.15 | $139.2K | 24,521 |
| Jan 26, 2026 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 3,746 | $37.15 | $139.2K | 0 |
| Jan 22, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 2,525 | $36.82 | $93.0K | 0 |
| Jan 22, 2026 | Dayno Jeffrey M. | PRESIDENT, CEO | Sell | 10,439 | $36.82 | $384.4K | 0 |
| Jan 22, 2026 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 4,792 | $36.82 | $176.4K | 0 |
| Jan 22, 2026 | Serafin Andrew | CHIEF STRATEGY OFFICER | Sell | 2,242 | $36.82 | $82.6K | 0 |
| Jan 20, 2026 | Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | Sell | 20,961 | $35.92 | $752.8K | 0Exit |
| Jan 15, 2026 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 20,961 | $35.92 | $752.8K | 0 |
| Dec 12, 2025 | Dayno Jeffrey M. | PRESIDENT, CEO | Sell | 25,933 | $40.11 | $1.04M | 0 |
| Dec 5, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 20,000 | $39.54 | $790.9K | 0 |
| Nov 21, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 3,427 | $35.00 | $119.9K | 0 |
| Sep 30, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 24,039 | $27.56 | $662.5K | 0 |
| Aug 15, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 21,573 | $36.50 | $787.4K | 0 |
| May 1, 2025 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 8,869 | $29.86 | $264.8K | 0 |
| Apr 1, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 6,987 | $32.54 | $227.4K | 0 |
| Mar 29, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 8,014 | $33.19 | $266.0K | 0 |
| Mar 3, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 4,869 | $32.67 | $159.1K | 0 |
| Jan 28, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 14,754 | $37.38 | $551.6K | 5,125-74% |
| Jan 28, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 1,775 | $38.05 | $67.5K | 0Exit |
| Jan 23, 2025 | Dayno Jeffrey M. | PRESIDENT, CEO | Sell | 19,293 | $40.13 | $774.2K | 0Exit |
| Jan 23, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 25,000 | $40.18 | $1.00M | 0Exit |
| Jan 21, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 30,598 | $37.51 | $1.15M | 0Exit |
| Jan 16, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 10,507 | $37.01 | $388.8K | 0Exit |
| Jan 15, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 7,180 | $37.04 | $265.9K | 0Exit |
| Nov 5, 2024 | Marshman Fund Trust II | 10% Owner | Sell | 4,600,000 | $30.30 | $139.39M8.0% OS | 6,651,120-41% |
| Nov 5, 2024 | Valor IV Pharma Holdings, LLC | 10% Owner | Sell | 4,600,000 | $30.30 | $139.39M8.0% OS | 7,218,033-39% |
| Oct 31, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 21,496 | $40.47 | $870.0K | 0Exit |
| Oct 7, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 36,357 | $35.06 | $1.27M | 705-98% |
| Oct 2, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 400 | $40.19 | $16.1K | 0Exit |
| Oct 1, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 35,846 | $40.03 | $1.43M | 0Exit |
| Sep 30, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 200 | $40.05 | $8.0K | 0Exit |
| Mar 18, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 11,979 | $32.00 | $383.3K | 0Exit |
| Mar 11, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 194 | $32.00 | $6.2K | 0Exit |
| Dec 16, 2022 | Nielsen Jack | Sell | 2,834 | $59.96 | $169.9K | 2,571,024 | |
| Dec 14, 2022 | Wicki Andreas | Director | Sell | 28,841 | $60.31 | $1.74M | 2,154,393 |
| Dec 9, 2022 | Nielsen Jack | Sell | 110,751 | $60.16 | $6.66M | 2,620,583 | |
| Dec 7, 2022 | Wicki Andreas | Director | Sell | 77,853 | $61.23 | $4.77M | 2,176,784 |
| Dec 5, 2022 | Serafin Andrew | CHIEF STRATEGY OFFICER | Sell | 38,000 | $60.13 | $2.29M | 920-98% |
| Dec 1, 2022 | Nielsen Jack | Sell | 129,652 | $59.29 | $7.69M | 2,792,928 | |
| Nov 22, 2022 | Nielsen Jack | Director | Sell | 77,600 | $57.27 | $4.44M | 2,871,061 |
| Nov 16, 2022 | Wicki Andreas | Director | Sell | 51,278 | $59.31 | $3.04M | 2,265,598 |
| Nov 15, 2022 | Nielsen Jack | Director | Sell | 158,400 | $57.58 | $9.12M | 3,013,461 |
| Nov 10, 2022 | Wicki Andreas | Director | Sell | 129,408 | $58.89 | $7.62M | 2,416,458 |
| Nov 4, 2022 | Dayno Jeffrey M. | CHIEF MEDICAL OFFICER | Sell | 15,000 | $60.02 | $900.3K | 0Exit |
| Nov 4, 2022 | Wicki Andreas | Director | Sell | 576,767 | $59.09 | $34.08M1.0% OS | 2,847,414 |
| Nov 2, 2022 | Dayno Jeffrey M. | CHIEF MEDICAL OFFICER | Sell | 15,000 | $55.10 | $826.6K | 0Exit |
| Oct 4, 2022 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 12,173 | $44.68 | $543.9K | 2,791-81% |
| Aug 23, 2022 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 28,971 | $47.00 | $1.36M | 2,321-93% |
| Aug 16, 2022 | Jacobs John C | PRESIDENT, CEO | Sell | 40,000 | $51.07 | $2.04M | 909-98% |
| Aug 10, 2022 | Wicki Andreas | Director | Sell | 578,552 | $53.77 | $31.11M1.0% OS | 3,104,282 |
Showing 1–50 of 95
1 / 2
HRMY Insider Buying Activity
The following table shows recent insider purchases of Harmony Biosciences Holdings, Inc. (HRMY) stock reported via SEC Form 4 filings.
No insider buying activity found for HRMY in the last 12 months.
HRMY Insider Selling Activity
The following table shows recent insider sales of Harmony Biosciences Holdings, Inc. (HRMY) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 28, 2026 | Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | Sell | 3,746 | $37.15 | $139.2K | 24,521 |
| Jan 26, 2026 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 3,746 | $37.15 | $139.2K | 0 |
| Jan 22, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 2,525 | $36.82 | $93.0K | 0 |
| Jan 22, 2026 | Dayno Jeffrey M. | PRESIDENT, CEO | Sell | 10,439 | $36.82 | $384.4K | 0 |
| Jan 22, 2026 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 4,792 | $36.82 | $176.4K | 0 |
| Jan 22, 2026 | Serafin Andrew | CHIEF STRATEGY OFFICER | Sell | 2,242 | $36.82 | $82.6K | 0 |
| Jan 20, 2026 | Kapadia Sandip | officer: CHIEF FINANCIAL OFFICER | Sell | 20,961 | $35.92 | $752.8K | 0Exit |
| Jan 15, 2026 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 20,961 | $35.92 | $752.8K | 0 |
| Dec 12, 2025 | Dayno Jeffrey M. | PRESIDENT, CEO | Sell | 25,933 | $40.11 | $1.04M | 0 |
| Dec 5, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 20,000 | $39.54 | $790.9K | 0 |
| Nov 21, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 3,427 | $35.00 | $119.9K | 0 |
| Sep 30, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 24,039 | $27.56 | $662.5K | 0 |
| Aug 15, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 21,573 | $36.50 | $787.4K | 0 |
| May 1, 2025 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 8,869 | $29.86 | $264.8K | 0 |
| Apr 1, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 6,987 | $32.54 | $227.4K | 0 |
| Mar 29, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 8,014 | $33.19 | $266.0K | 0 |
| Mar 3, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 4,869 | $32.67 | $159.1K | 0 |
| Jan 28, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 14,754 | $37.38 | $551.6K | 5,125-74% |
| Jan 28, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 1,775 | $38.05 | $67.5K | 0Exit |
| Jan 23, 2025 | Dayno Jeffrey M. | PRESIDENT, CEO | Sell | 19,293 | $40.13 | $774.2K | 0Exit |
| Jan 23, 2025 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 25,000 | $40.18 | $1.00M | 0Exit |
| Jan 21, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 30,598 | $37.51 | $1.15M | 0Exit |
| Jan 16, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 10,507 | $37.01 | $388.8K | 0Exit |
| Jan 15, 2025 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 7,180 | $37.04 | $265.9K | 0Exit |
| Nov 5, 2024 | Marshman Fund Trust II | 10% Owner | Sell | 4,600,000 | $30.30 | $139.39M8.0% OS | 6,651,120-41% |
| Nov 5, 2024 | Valor IV Pharma Holdings, LLC | 10% Owner | Sell | 4,600,000 | $30.30 | $139.39M8.0% OS | 7,218,033-39% |
| Oct 31, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 21,496 | $40.47 | $870.0K | 0Exit |
| Oct 7, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 36,357 | $35.06 | $1.27M | 705-98% |
| Oct 2, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 400 | $40.19 | $16.1K | 0Exit |
| Oct 1, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 35,846 | $40.03 | $1.43M | 0Exit |
| Sep 30, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 200 | $40.05 | $8.0K | 0Exit |
| Mar 18, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 11,979 | $32.00 | $383.3K | 0Exit |
| Mar 11, 2024 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 194 | $32.00 | $6.2K | 0Exit |
| Dec 16, 2022 | Nielsen Jack | Sell | 2,834 | $59.96 | $169.9K | 2,571,024 | |
| Dec 14, 2022 | Wicki Andreas | Director | Sell | 28,841 | $60.31 | $1.74M | 2,154,393 |
| Dec 9, 2022 | Nielsen Jack | Sell | 110,751 | $60.16 | $6.66M | 2,620,583 | |
| Dec 7, 2022 | Wicki Andreas | Director | Sell | 77,853 | $61.23 | $4.77M | 2,176,784 |
| Dec 5, 2022 | Serafin Andrew | CHIEF STRATEGY OFFICER | Sell | 38,000 | $60.13 | $2.29M | 920-98% |
| Dec 1, 2022 | Nielsen Jack | Sell | 129,652 | $59.29 | $7.69M | 2,792,928 | |
| Nov 22, 2022 | Nielsen Jack | Director | Sell | 77,600 | $57.27 | $4.44M | 2,871,061 |
| Nov 16, 2022 | Wicki Andreas | Director | Sell | 51,278 | $59.31 | $3.04M | 2,265,598 |
| Nov 15, 2022 | Nielsen Jack | Director | Sell | 158,400 | $57.58 | $9.12M | 3,013,461 |
| Nov 10, 2022 | Wicki Andreas | Director | Sell | 129,408 | $58.89 | $7.62M | 2,416,458 |
| Nov 4, 2022 | Dayno Jeffrey M. | CHIEF MEDICAL OFFICER | Sell | 15,000 | $60.02 | $900.3K | 0Exit |
| Nov 4, 2022 | Wicki Andreas | Director | Sell | 576,767 | $59.09 | $34.08M1.0% OS | 2,847,414 |
| Nov 2, 2022 | Dayno Jeffrey M. | CHIEF MEDICAL OFFICER | Sell | 15,000 | $55.10 | $826.6K | 0Exit |
| Oct 4, 2022 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 12,173 | $44.68 | $543.9K | 2,791-81% |
| Aug 23, 2022 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 28,971 | $47.00 | $1.36M | 2,321-93% |
| Aug 16, 2022 | Jacobs John C | PRESIDENT, CEO | Sell | 40,000 | $51.07 | $2.04M | 909-98% |
| Aug 10, 2022 | Wicki Andreas | Director | Sell | 578,552 | $53.77 | $31.11M1.0% OS | 3,104,282 |
HRMY Insiders
Similar Stocks to HRMY
VRTX
Vertex Pharmaceuticals Incorporated
$436.80-3.02%
$114.32B
REGN
Regeneron Pharmaceuticals, Inc.
$699.83-1.87%
$73.44B
ALNY
Alnylam Pharmaceuticals, Inc.
$289.07-1.46%
$39.18B
RVMD
Revolution Medicines, Inc.
$145.16-2.80%
$31.78B
INSM
Insmed Incorporated
$109.78-5.14%
$25.06B
UTHR
United Therapeutics Corporation
$568.58-1.47%
$24.13B
ROIV
Roivant Sciences Ltd.
$29.29-0.08%
$20.96B
MRNA
Moderna, Inc.
$49.04-2.34%
$19.46B